AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04428658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Usual quarterly visits with the UCD Pediatric Diabetes Clinic.
Study NCT04428658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Usual quarterly visits with the UCD Pediatric Diabetes Clinic.
Study NCT04428658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supplemental remote monitoring
Description: Receiving remote glucose monitoring with monthly outreach from a pediatric endocrinologist as a supplement to regular diabetes clinic visits.
Study NCT06637371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 691
Description: Subcutaneous (SC) injection
Study NCT06637371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injection
Study NCT05712200 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abelacimab
Description: Abelacimab provided as liquid in vial (150 mg/mL)
Study NCT05712200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage Formulation: Liquid (in vial)~Dose Strength: Placebo to Abelacimab
Study NCT06291376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Participants will receive ravulizumab via weight-based intravenous (IV) infusion.
Study NCT06291376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo via weight-based IV infusion.
Study NCT04372108 — intervention group
Intervention type: DRUG
Intervention: Ustekinumab
Description: Participants who are new users of ustekunumab will be included in the cohort. No study treatment will be administered as a part of this study.
Study NCT04372108 — intervention group
Intervention type: DRUG
Intervention: Other Biologic Therapies
Description: Participants who are new users of other biologic therapies (for examples for example, infliximab, adalimumab, or vedolizumab administered as per the prescription record) will be included in this cohort. No study treatment will be administered as a part of this study.
Study NCT06320990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20mg
Description: Tamoxifen is a nonsteroidal antiestrogen for oral administration.
Study NCT02531880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mangafodipir
Description: Patients will be imaged interictally with a gadolinium enhanced MRI session. The administration of mangafodipir will be done as an inpatient during long-term video EEG recording, to ensure administration in the peri-ictal period.
Study NCT06739395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Capsules
Description: Usage and dosage: For patients weighing less than 60kg, the recommended daily dose of lenvatinib is 8mg once a day; For patients weighing ≥ 60kg, the recommended daily dose of lenvatinib is 12mg once daily. Lunvatinib should be taken at a fixed time every day, on an empty stomach or with food.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Study NCT06561373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm & Alert yoga and mindfulness
Description: The Calm \& Alert protocol is multisensorial, with successive opportunities to practice the explicit concepts taught throughout the lessons using yoga and mindfulness-techniques. Each class has a similar structure of songs, breathing, warm-ups, yoga poses, mindful games, and rest involving meditation with child-friendly language. The study includes the recommended materials of a Hoberman sphere (breathing ball), chime, mind/body/breath icons, two small mason jars (one with mud and one with clear water), yoga mats for students, pictures of feelings (happy, sad, angry, scared, surprised, disgusted), and an on/off switch.
Study NCT04717960 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nasal submucosal injection of platelet rich plasma
Description: * The selected region will be inﬁltrated with a cold saline solution with addition of 1 mL of adrenaline and 25 mL of 2% lignocaine per 500 mL saline.~* Platelet-rich plasma is prepared by drawing 10 mL of blood sample from the patient.~* The blood will be centrifuged at 1530 g for 10 min to obtain platelet-poor plasma.~* This will again centrifuged at 2720 g for 10 min to get platelet-rich plasma.~* Approximately 1 mL of platelet-rich plasma will be obtained from 10 mL blood. Usually amount of about 3ml is needed to be injected in each nostril at the affected sites of inferior and middle turbinates, septum and floor of the nose. Platelet rich plasma injected into the affected area after degranulating the platelet by adding 0.5 mL of calcium chloride.~  * Injection interval of 2 weeks (up to total 3 consecutive injections).~ * Follow-up duration: 4 months
Study NCT06562049 — intervention group
Intervention type: RADIATION
Intervention: musculoskeletal ultrasound
Description: musculoskeletal ultrasound on both hands
Study NCT06739395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Pill
Description: Usage and dosage: In the safety introduction section, the initial dose of pazopanib is 400mg, and in the dose escalation queue, the dose of pazopanib is 600mg.The dosage for combined use will be adaptively adjusted by the researcher.~Administration method: Oral treatment once a day, with a cycle of 28 days.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Study NCT06468371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine Agonist (Ropinirole)
Description: Ropinirole administration will start at 0.25 mg orally once daily, two hours before bedtime. The dose will be adjusted weekly based on symptoms, increasing by 0.5 mg increments, up to a maximum of 2.0 mg, which will be maintained for the remaining 12 weeks.
Study NCT06468371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Excercise training
Description: Exercise sessions will involve using a pedal bicycle twice a week for 12 weeks, integrated into the patients' hemodialysis schedule. Each session will last 20 minutes, scheduled between the second and third hours of dialysis. The first 5 minutes will be for warm-up with slow pedaling, followed by 10 minutes of intense pedaling, and concluding with a 5-minute cool-down period of slow pedaling to gradually reduce the heart rate.
Study NCT04751500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient hysteroscopy
Description: Direct visualisation and careful extraction of retained pregnancy tissue using a specific hysteroscopic technology known as a hysteroscopic tissue retrieval system.
Study NCT04751500 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expectant management
Description: Leaving the retained pregnancy tissue alone to pass by itself
Study NCT04751500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical management
Description: Giving medications to contract the womb to pass the retained pregnancy tissue
Study NCT04751500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Giving antibiotics to reduce any inflammation/infection caused by the retained pregnancy tissue allowing it to pass by itself
Study NCT04751500 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical management
Description: Passing a small cannula/catheter/currette into the womb and mechanically scraping the womb lining to remove the retained pregnancy tissue
Study NCT05004675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lerodalcibep
Description: 300 mg
Study NCT05004675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inclisiran
Description: 284 mg
Study NCT06739395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib Pill
Description: Usage, dosage, and administration method: 100mg, orally administered once daily for 21 consecutive days, followed by a 7-day discontinuation; Every 28 days is a treatment cycle.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Study NCT06739395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Usage and dosage: It is recommended to take 30mg (6 tablets) each time, twice a week, with an interval of no less than 3 days between each dose (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.). It should be taken 30 minutes after breakfast.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Study NCT06739395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1/PD-1&CTLA4 inhibitor
Description: Refer to the respective instructions for use, and the dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Study NCT06739395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Target Gene
Description: Granting CFDA or FDA approved drugs(off-label approved drugs) based on specific molecular characteristics.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Study NCT06524921 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental pulpectomy using metapex
Description: Metapex: A dental pulpectomy treats tooth with irreversible pulpitis in primary and teeth by removing infected pulp tissue using files and irrigation in the radicular part. The procedure involves anesthesia, decay removal, pulp chamber access, filing and irrigation till we reach cleaned dried canals and applying a medicament like Metapex . The tooth is then restored with a filling, often a stainless steel crown. The loss of pulp tissue weakens the tooth's structure and increases the risk of fracture and infection.
Study NCT06524921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental pulpectomy using biodentine
Description: Biodentine: A dental pulpotomy treats tooth decay or trauma in primary and young permanent teeth by removing infected pulp tissue in the crown while preserving healthy root pulp. The procedure involves anesthesia, decay removal, pulp chamber access, hemostasis, and applying a medicament like MTA or Biodentine. The tooth is then restored with a filling, often a stainless steel crown. Pulpotomies preserve tooth structure, relieve pain, and are less invasive than full root canals, but require regular follow-up.
Study NCT05344053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based precise management
Description: The community-based precise management is a modified management strategy beyond the traditional standard community-based care under the hierarchical medical system of China. In the intervention arm, the community doctors receive training to improve their skills on coronary artery disease management. Patients will be under management for 1 year according to the strategies of community-based precise management and rehabilitation model.
Study NCT05344053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard community-based management
Description: The standard community-based management is the usual community-based care under the hierarchical medical system of China. In this arm, the community doctors will not receive any training on precise management strategies to improve their skills on coronary artery disease management, and patients will be under usual care for 1 year.
Study NCT05305248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: After spinal anesthesia, 5 mg of remimazolam is injected by intravenous route for 1 minute to induce sedation. To maintain sedation, remimazolam is continuously infused at a rate within the range of 0.1 mg/kg/h to 1 mg/kg/h.
Study NCT05305248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: After performing spinal anesthesia, dexmedetomidine is injected at a loading dose of 1 mcg/kg for 10 minutes to induce sedation. Thereafter, to maintain sedation, Dexmedetomidine is continuously infused at a rate within the range of 0.2 to 0.7 mcg/kg/h.
Study NCT06253403 — intervention group
Intervention type: BEHAVIORAL
Intervention: psychotherapy
Description: psychotherapy related to sexual intervention
Study NCT05963230 — intervention group
Intervention type: OTHER
Intervention: Ultrasound scans
Description: Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
Study NCT05548855 — intervention group
Intervention type: PROCEDURE
Intervention: Heart Transplant
Description: Patients who have undergone a heart transplant as standard of care (SOC) procedure
Study NCT05548855 — intervention group
Intervention type: DEVICE
Intervention: Cardiac Assistive Device
Description: Patients who have undergone a placement of a cardiac assistive device
Study NCT04677569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALIS
Description: Inhalation via nebulization over approximately 6 to 15 minutes
Study NCT05710172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory Mirror Therapy
Description: 21 days, up to 3 hours per day intervention
Study NCT05710172 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Auditory Mirror Therapy
Description: 21 days, up to 3 hours per day intervention
Study NCT05611736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold saline
Description: After standard chemo-mechanical preparation of the root canal, final irrigation will be performed using 20 milliliters of cold (at 2.5 degrees Celsius temperature) saline solution.
Study NCT04863716 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane Block will be administered before the surgery.
Study NCT05611736 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: After standard chemo-mechanical preparation of the root canal, final irrigation of the root canal will be done using normal saline solution at room temperature
Study NCT05130983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExoFlo
Description: Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
Study NCT06181500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based multicomponent exercise intervention program
Description: A novel home-based multicomponent exercise intervention program was designed using a multimodal training circuit. This 24-week circuit program was created to improve functional (resistance) and aerobic health. Participants will be asked to train two to three times a week for 45 minutes. They will be supervised via videoconference by a trained kinesiologist from the EPIC Center at the Montreal Heart Institute. If desired, participants can complete their exercises with a partner, friend, or relative to facilitate communication. Participants will be asked to document the perceived intensity of their exercises in a booklet after each workout. The perceived intensity of their exercises will be measured by a validated effort perception scale graduated from 0 to 10 (Borg scale; Williams, 2017). Progressions will increase every five weeks and will be subject to modification if not properly tolerated or if found to be below a 3 on the Borg rate of perceived exertion scale (moderate intensity).
Study NCT05017155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine
Description: Mexiletine is a sodium channel blocker shown to be effective in reducing myotonia in a multi-centre randomised trial.
Study NCT05017155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine 25Mg Oral Tablet, Extended Release
Description: Lamotrigine is an alternative sodium channel blocker that has been shown to be effective in one randomised controlled trial. It is currently used as a licensed medication for other neurological conditions.
Study NCT06231121 — intervention group
Intervention type: DRUG
Intervention: Faricimab
Description: The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
Study NCT04863716 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fentanyl patient control device
Description: 24-hour fentanyl consumption will be recorded.
Study NCT04677569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Oral tablet
Study NCT05829057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous injection of P-IL-2
Description: Ia :Single dose intravenous injection of P-IL-2；
Study NCT05829057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-IL-2 plus Anti-PD-1 Monoclonal Antibody
Description: Ib：P-IL-2 plus Anti-PD-1 Monoclonal Antibody；
Study NCT05221190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single buccal infiltration
Description: injecting local anaesthetic solution into the soft tissues of the buccal sulcus adjacent to the target tooth.
Study NCT05221190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior alveolar nerve block
Description: Injection of local anesthetic solution into the pterygomandibular space to access the inferior alveolar nerve before it enters the mandible.
Study NCT05301244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laughter yoga for nurses
Description: The experimental group was divided into three groups as 17-17-16 people. For four weeks, laughter yoga sessions were held between 20.00 and 21.00, 2 days a week for each group. Laughter yoga sessions were held for the 1st group between 20.00-21.00 on Mondays and Thursdays, for the 2nd group between 20.00-21.00 on Tuesdays and Fridays, and for the 3rd group between 20.00-21.00 on Wednesdays and Sundays. The first sessions lasted 45 minutes, every other session 40 minutes.
Study NCT05301244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laughter yoga for nurses-Deep breathing exercises
Description: Deep breathing exercises (5 minutes) Breathing is held for 4-5 seconds after deep inspiration. While the arms are brought to the normal position, exhale slowly and rhythmically. When expressing after deep inspiration, the lips can be pursed as if whistling or exhaled with laughter.
Study NCT05301244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laughter yoga for nurses-Warm-up exercises
Description: Warm-up exercises (10 minutes) Rhythm of 1-2, 1-2-3 is added to increase the energy level even more and synchronize the movements of the group. After a few rhythmic clapping movements, another movement is added. Whisking hands left and right. Then an audible rhythm of ho, ho, ha-ha-ha is added to the clapping gesture. Make eye contact with people in the group and smile at them.
Study NCT05301244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laughter yoga for nurses-Childish games
Description: Childish games (10 minutes) Childlike games are used to help laugh without reason just like a child. The group is motivated by visualizing these games in their minds, raising the arms up in the form of a Y letter, and saying very good (applause), very good (applause), hey with palms facing the sky.
Study NCT05301244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laughter yoga for nurses-Laughter exercises
Description: Laughter exercises (15 minutes) This section includes a variety of laughter exercises such as greetings, strawberry milk, conductor, bonus, hot soup, lion, aloha, bird, appreciation, laughter lotion, elevator, cream cake, and bursting balloon laughter.
Study NCT04677569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: Oral tablet
Study NCT04677569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Oral tablet
Study NCT04677569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethambutol
Description: Oral tablet
Study NCT04677569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ELC (matching placebo for ALIS)
Description: Inhalation via nebulization over approximately 6 to 15 minutes